Key result
OKT3 use in transplant recipients may be associated with the enhancement of Epstein-Barr virus infections.
Why the study?
Does OKT3 enhance Epstein-Barr virus infections in transplant recipients?
Population
Transplant recipients
Design
Other
Authors
Loading...
May prompt EBV monitoring with OKT3; leaves open confirmation of association in prospective studies.
Does OKT3 enhance Epstein-Barr virus infections in transplant recipients?
The use of OKT3 in transplant recipients may possibly enhance Epstein-Barr virus infections.
Ren et al. (1988) studied this question. OKT3 use in transplant recipients may be associated with the enhancement of Epstein-Barr virus infections.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: